iPS Cell Model for CFC Syndrome Neural Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying cardiofaciocutaneous syndrome (CFC syndrome) lack a reliable model for understanding neural development and treating the condition, as the association with RAS-MAPK signaling pathway mutations is unclear, and direct p-ERK inhibitors pose risks for cell proliferation and differentiation side effects.
Innovation Solution
Development of an induced pluripotent stem cell (iPS) model from CFC syndrome patient fibroblasts, allowing for in vitro differentiation into embryonic bodies and neurons, with the use of p-ERK and p-SMAD1 inhibitors to restore normal differentiation and shape, facilitating the screening of drug candidates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct p-ERK inhibitors are used to treat CFC syndrome, then the signaling pathway is blocked, but side effects occur in cell proliferation and differentiation
Solution Approach 1:
The patent uses an iPS cell model as an intermediary system to study CFC syndrome pathogenesis and screen drugs. This intermediary model allows indirect investigation of disease mechanisms without directly applying harmful inhibitors to patients, enabling safe drug discovery while maintaining treatment effectiveness goals
Solution Approach 2:
The patent performs preliminary drug screening using the iPS cell model before clinical application. By pre-testing compounds in the controlled iPS system, harmful side effects can be identified and avoided before treating actual patients, thus preventing the worsening of cell proliferation and differentiation
2Object-generated harmful factors
If induced pluripotent stem cells are used to model CFC syndrome, then neural development mechanisms can be studied, but the complexity of the model system increases
Solution Approach 1:
The patent creates a simplified copy of CFC syndrome pathology using iPS cells derived from patient fibroblasts. This cellular copy replicates the essential disease characteristics (abnormal neural differentiation) without requiring complex whole-organism models, thus providing a reliable yet manageable model system for studying neural development mechanisms
3Reliability
If CFC syndrome patient fibroblasts are converted to iPS cells, then disease characteristics are preserved, but the differentiation process becomes complex and difficult to control
Solution Approach 1:
The patent systematically adjusts differentiation parameters (growth factors, culture conditions, time points) to optimize neural differentiation of CFC-iPS cells. By controlling these parameters, the complex differentiation process becomes manageable while preserving the essential disease characteristics in the resulting neural cells
Data Source
AI summary
The present invention relates to an induced pluripotent stem cell (iPS) model for cardiofaciocutaneous (CFC) syndrome, a method for producing the model, and uses of the iPS model in the analysis of neural development in CFC syndrome. Specifically, the CFC syndrome-derived iPS and generation and differentiation of an embryonic body were induced from the fibroblasts of a CFC syndrome patient, and the CFC syndrome-derived iPS and embryonic body were confirmed to exhibit broken embryonic body shapes and no differentiation into neurons. When a CFC syndrome-derived embryonic body was induced by treating with p-ERK and p-SMAD1 inhibitors, the embryonic body exhibited a normal embryonic body shape and effectively differentiated into neurons. Thus, the CFC syndrome patient-derived stem cell model of the invention can be effectively used in the research for neural development in cardiofaciocutaneous syndrome.